Astellas Pharma Inc: Carcinoma, Non-Small-Cell Lung trials

The registry lists 26 Carcinoma, Non-Small-Cell Lung studies with Astellas Pharma Inc as lead sponsor. 5 are open to participants now and 6 have results posted.

Phase 1 13Phase 2 14Phase 3 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D MutationRecruitingNCT07566052Phase 3
• A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsRecruitingNCT07488676Phase 1/2
• A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid TumorsRecruitingNCT07287995Phase 1/2
• A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)RecruitingNCT07140016Phase 1
• A Study to Find a Suitable Dose of ASP5834 in Adults With Solid TumorsRecruitingNCT07094204Phase 1
• A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)Active, not recruitingNCT04225117Phase 2Results posted
• A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating MutationsTerminatedNCT02588261Phase 3Results posted
• A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)TerminatedNCT02495233Phase 1/2Results posted
• A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive TumorsCompletedNCT00373425Phase 3Results posted
• Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLCCompletedNCT00294762Phase 2Results posted
• Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2CompletedNCT00085839Phase 2Results posted
• XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.Active, not recruitingNCT06792435Phase 1/2
• A Study to Find a Suitable Dose of ASP4396 in Adults With Solid TumorsTerminatedNCT06364696Phase 1
• A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) MutationsTerminatedNCT03082300Phase 1
• A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR MutationsTerminatedNCT02500927Phase 2
• An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) MutationsTerminatedNCT02192697Phase 1/2
• A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) MutationsCompletedNCT02113813Phase 1
• Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) GeneCompletedNCT01221077Phase 2
• Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based ChemotherapyCompletedNCT01186861Phase 2
• A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)CompletedNCT00739453Phase 1
• Phase 1 Study of OSI-930 in Cancer PatientsCompletedNCT00513851Phase 1
• LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With ChemotherapyCompletedNCT00328588Phase 2
• A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer PatientsCompletedNCT00085826Phase 3
• Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00072631Phase 2
• Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) PatientsCompletedNCT00072618Phase 1/2
• OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00036647Phase 3